Private Equity

Updated:

NextGen Capital Partners

NextGen Capital Partners is a private equity firm based in München, Germany. It focuses on venture capital investments. The firm has a team of two staff,...

NextGen Capital Partners logo

NextGen Capital Partners

NextGen Capital Partners is a private equity firm based in München, Germany. It focuses on venture capital investments. The firm has a team of two staff, including two investment professionals.

General information

Firm type

Private Equity

Location

Region

Europe

Country

Germany

City

Munich

Corporate office

Munich, Germany

Sector focus

Life SciencesHealthcare ServicesDigital HealthBiotechnology

Frequently asked questions

What investment stages does NextGen Capital Partners target?

NextGen invests from early stage through growth, covering seed, Series A, and expansion rounds. The firm focuses on companies that have progressed beyond pure preclinical research and are advancing toward clinical validation or commercial launch.

Which sectors does NextGen Capital Partners explicitly avoid?

The firm does not invest outside life sciences — it avoids general technology, consumer, industrial, and financial services sectors. Its mandate is restricted to biotechnology, medical devices, digital health, and healthcare services.

How does NextGen source its investment opportunities?

NextGen sources opportunities through its network within European academic medical centers, biotech incubators, and research institutions, particularly in Germany and Switzerland. Proximity to Munich's life sciences cluster provides direct access to spinouts and early-stage ventures.

Does NextGen operate as a single family office or institutional fund manager?

NextGen Capital Partners operates as an institutional asset manager, not a family office. The firm manages pooled investment vehicles for external investors, focusing exclusively on European life sciences private equity.

What is NextGen's geographic investment focus?

NextGen concentrates on Germany, Switzerland, and Western Europe, leveraging Munich's position as a leading biotech hub. The firm may evaluate opportunities in Scandinavia and the United Kingdom when aligned with its therapeutic and digital health themes.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Munich Private Equity profiles